Adaptimmune, a spin-out of Oxford University developing immunotherapy treatments targeted against cancer, has raised $191.3m in its IPO.
Trading on Nasdaq under the ticker ADAP, the firm placed 11,250,000 at $17 per share. The firm blew out its original target of $175.7m during the offering.
Formed in 2008, the company is using genetically engineered T-cells to treat cancer and other infectious diseases. Adaptimmune has collaboration agreements in place with pharmaceutical firm GlaxoSmithKline, and raised $104m last year in a series…
